,address1,address2,city,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,dividendRate,dividendYield,exDividendDate,payoutRatio,fiveYearAvgDividendYield,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,earningsQuarterlyGrowth,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,earningsGrowth,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Mr. Masashi  Miyamoto Ph.D.', 'age': 63, 'title': 'Pres, CEO & Representative Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 874620, 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
1,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Mr. Yutaka  Osawa M.B.A.', 'age': 63, 'title': 'CCO & Representative Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 528840, 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
2,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Mr. Motohiko  Kawaguchi', 'title': 'CFO & Head of Global Fin.', 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
3,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Kazuki  Nemoto', 'title': 'Head of Global Legal', 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
4,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Satoko  Yoshida M.B.A.', 'title': 'Head of Global Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
5,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Hiroshi  Sonekawa', 'title': 'Head of Japan Sales & Marketing', 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
6,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Wataru  Murata M.B.A.', 'title': 'Chief People Officer & Head of Global HR', 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
7,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Takeyoshi  Yamashita Ph.D.', 'title': 'Chief Medical Officer Sr., Sr. Managing Exec. Officer & Director', 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
8,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Yasuo  Fujii M.B.A.', 'title': 'Chief Strategy Officer, VP & Managing Exec. Officer,', 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
9,Otemachi Financial City Grand Cube,"1-9-2, Otemachi Chiyoda-ku",Tokyo,100-0004,Japan,81 3 5205 7200,https://www.kyowakirin.com,Drug Manufacturers—General,Healthcare,"Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.",5982,"{'maxAge': 1, 'name': 'Jean-David  Rafizadeh-Kabe J.D., M.D.', 'title': 'Head of Global Pharmacovigilance', 'exercisedValue': 0, 'unexercisedValue': 0}",1,1,1,2,1,1693526400,1672444800,86400,2,16.7,16.8,16.8,16.8,16.7,16.8,16.8,16.8,0.38,0.0227,1703721600,0.7221,1.63,0.158783,35.74468,20.487804,37,37,2,3,3,16.8,17.5,129600,126400,9223585792,15.9,24.0,0.022370566,16.55,18.9895,27.0,1.6167665,EUR,-363360452608,0.0975,248550119,537606976,0.53683996,0.20414,1478.379,0.011363797,1672444800,1703980800,1688083200,-0.532,40201998336,0.47,0.82,-0.881,-4.265,FRA,EQUITY,KY4.F,KY4.F,KYOWA KIRIN CO. LTD.,"Kyowa Kirin Co., Ltd.",955692000,Europe/Berlin,CEST,7200000,16.8,none,372392001536,692.704,85191999488,0,3.932,4.671,412308996096,767.077,0.04321,0.05153,311456000000,23747624960,86559997952,-0.532,0.084,0.78031,0.20662001,0.16093999,JPY,
